home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2925.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
37 lines
Document 2925
DOCN M94A2925
TI Risk of neuropsychological impairment steadily rises from date of
seroconversion: HNRC experience.
DT 9412
AU Grant I; Heaton RK; Deutsch R; McCutchan JA; Atkinson JH; Chandler J;
University of California, San Diego, La Jolla.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):193 (abstract no. PB0200). Unique
Identifier : AIDSLINE ICA10/94369650
AB OBJECTIVE: Neuropsychological (NP) impairment is prevalent in persons
with AIDS, but the natural course of such impairment is poorly
understood. We explored risk of NP impairment as a function of years
since seroconversion. METHODS: The 152 non-intravenous drug using HIV+
men all had documented dates of negative and positive ELISAs from which
approximate time of seroconversion could be estimated. Comprehensive NP
testing included the extended Halstead-Reitan battery. Survival analysis
was used to determine the hazard of NP impairment in relation to years
from seroconversion. RESULTS: The Kaplan-Meier plot for time to NP
impairment revealed that at each successive year from seroconversion the
risk of becoming impairment was increased, rising from 11%, 14%, to 17%
in the first 3 years, and then to 26% and 41% in years 4 and 5.
CONCLUSION: The risk of NP impairment rises steadily with length of
seropositivity. This is true even for a largely medically asymptomatic
sample. Our findings contrast with data from some other groups who have
asserted that risk of NP impairment is negligible until patients become
symptomatic. These data emphasize the importance of comprehensive
neurobehavioral studies of samples of seropositive individuals in whom
dates of seroconversion can be estimated reliably.
DE Adult AIDS Dementia Complex/*DIAGNOSIS/EPIDEMIOLOGY Follow-Up Studies
Human HIV Seropositivity/*DIAGNOSIS/EPIDEMIOLOGY Male
*Neuropsychological Tests Proportional Hazards Models Risk Factors
Survival Analysis MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).